Pharmaceutical companies are shifting from the development of autologous cell therapies to allogeneic cell therapies.

The life science group Sartorius is launching an integrated system for the production and quality control (QC) of autologous cell therapies.

Shares of ImmunityBio IBRX rose more than 7% on Friday after the company announced that it completed two manufacturing ...

ImmunityBio (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced the successful completion of manufacturing engineering programs, NK2022 and NK2023, establishing a safe, ...

Cell therapy, one of the most promising frontiers in modern medicine, holds the potential to cure once-incurable diseases such as cancer and genetic disorders. But for all its promise, manufacturing ...

The AMT designation gives Cellares’ clients using the Cell Shuttle priority review with the FDA leading to accelerated regulatory filings SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cellares, the ...

The first half of 2025 has been a notable one for Cellares. The cell therapy manufacturer operates its first commercial-scale Integrated Development and Manufacturing Organization Smart Factory in ...

Shares of ImmunityBio (IBRX) gained more than 3% in pre-market trading on Friday, after the pharmaceutical firm announced on Friday the completion of key manufacturing engineering programs supporting ...

The "Cell and Gene Therapy Manufacturing Market -- Growth, Share, Opportunities & Competitive Analysis, 2024 -- 2032" report has been added to the Credence Research Inc. offering. The global Cell and ...

In this innovation spotlight, Tia Harmon, technical science liaison, CGT for PHC Corporation of North America (PHCNA), discusses the key challenges in CGT manufacturing and how in-line monitoring ...

This story is republished from STAT, the health and medicine news site that’s a partner to the Globe. Sign up for STAT’s free Morning Rounds newsletter here. Vertex executives warned that Casgevy, its ...